BTG.L on London Stock Exchange

19 Dec 2014
Price Change (% chg)

-1.50p (-0.19%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for BTG.L


BTG plc is an international specialist healthcare company. The Company is focused on three business areas: Specialty Pharmaceuticals, Interventional Medicine and Licensing & Biotechnology. Its focus within Specialty Pharmaceuticals is on antidote products that are used within hospitals. Its interventional medicine products are... (more)


Beta: 0.37
Market Cap (Mil.): £3,068.86
Shares Outstanding (Mil.): 381.70
Dividend: --
Yield (%): --


  BTG.L Industry Sector
P/E (TTM): 73.93 37.83 38.47
EPS (TTM): 0.11 -- --
ROI: 6.13 18.99 18.25
ROE: 7.14 19.75 19.13
Search Stocks

BRIEF-BTG raises about 150 mln stg by placing new shares

* Placing raised proceeds of approximately 150 mln stg (before expenses)

04 Dec 2014

CORRECTED-BRIEF-BTG to acquire Pneumrx for up to $475 mln, funded by placing

* Announce that it has entered into an agreement to acquire pneumrx inc on a debt free cash free basis for an initial cash consideration of us$230 million

04 Dec 2014

BTG to buy lung intervention firm for up to $475 mln

LONDON, Dec 4 - BTG, the healthcare group best known for treating rattlesnake bites and varicose veins, is expanding into lung care by buying a Californian firm that has developed a device to prop open airways.

04 Dec 2014

BTG says long-awaited varicose vein treatment has positive debut

Nov 11 - British drugs company BTG said it had started to roll out its varicose vein treatment to a positive response in the United States, as it said revenue for the year would be at the top end of forecasts.

11 Nov 2014

BRIEF-BTG posts rise in H1 profit, sees full-year revenue at top end

* Operating profit increased to £42.8m (h1 13/14: £25.0m)

11 Nov 2014

BRIEF-BTG to supply DC Bead, Bead Block directly to doctors in Europe

* To supply DC Bead and Bead Block directly to physicians in Europe from 1 April 2015

13 Oct 2014

BRIEF-BTG settles Crofab patent litigation case against Bioclon, RDT

* BTG would allow Bioclon to begin selling crotalid antivenom relying on BTG's 414 patent from October 2018

10 Oct 2014

Earnings vs. Estimates

Search Stocks